This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutAboutBroad CoverageIndicationsEfficacyEfficacyEfficacyLimited Treatment OptionsSafetySafetySafetyDosingDosingAdult DosingPaediatric Dosing
Zavicefta (ceftazidime-avibactam) has a safety and tolerability profile consistent with both cephalosporins and carbapenems1-4
  • Overall rates of any AE were low in the ZAVICEFTA (ceftazidime–avibactam) and comparator arms1-4
  • Rates of all other categories of AEs were low and balanced across treatment arms1-4
  • Most common (≥ 5%) AEs for ZAVICEFTA were positive direct Coombs test, nausea and diarrhoea5*
  • Nausea and diarrhoea were usually mild or moderate in intensity1-5
  • No requirement for routine monitoring and a low potential for drug–drug interactions5
  • In four Phase III clinical trials, the adverse-event profile of ZAVICEFTA was similar to that seen with either best-available therapy, doripenem or meropenem.1-4
*Based on data from seven Phase II and Phase III clinical trials in 2024 adult patients treated with ZAVICEFTA.5Prescribing information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate)

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for
solution for infusion

Meronem® (meropenem trihydrate) 

Meronem® (Meropenem Trihydrate) Meronem I.V. 1g

Abbreviations:AE, adverse event; References:Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9.Carmeli Y, et al. Lancet Infect Dis 2016;16:661–73.Torres A, et al. Lancet Infect Dis 2018;18:285–95.Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62.ZAVICEFTA. Summary of Product Characteristics, 2022.

Legal Category: S1A

Further information available upon request

PP-ZVA-IRL-0240. December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.